| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895557 | JANSSEN PRODS | Pharmaceutical formulations of ecteinascidin compounds |
Jan, 2028
(3 years from now) | |
|
US8895557 (Pediatric) | JANSSEN PRODS | Pharmaceutical formulations of ecteinascidin compounds |
Jul, 2028
(4 years from now) | |
Yondelis is owned by Janssen Prods.
Yondelis contains Trabectedin.
Yondelis has a total of 2 drug patents out of which 0 drug patents have expired.
Yondelis was authorised for market use on 23 October, 2015.
Yondelis is available in powder;intravenous dosage forms.
Drug patent challenges can be filed against Yondelis from 23 April, 2022.
The generics of Yondelis are possible to be released after 07 July, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 23, 2020 |
| Orphan Drug Exclusivity(ODE) | Oct 23, 2022 |
| Orphan Drug Exclusivity(ODE-100) | Oct 23, 2022 |
| M(M-232) | Jun 29, 2021 |
| Pediatric Exclusivity(PED) | Apr 23, 2023 |
Drugs and Companies using TRABECTEDIN ingredient
NCE-1 date: 23 April, 2022
Market Authorisation Date: 23 October, 2015
Treatment: NA
Dosage: POWDER;INTRAVENOUS
How can I launch a generic of YONDELIS before it's drug patent expiration?
More Information on Dosage
YONDELIS family patents
